Hirudin
From Proteopedia
(Difference between revisions)
| (14 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | + | <StructureSection load='4htc' size='350' side='right' caption='Hirudin (green) complex with glycosylated thrombin small subunit (aqua) and large subunit (magenta) (PDB entry [[4htc]])' scene='41/417483/Cv/2'> | |
| + | == Function == | ||
| + | [[Hirudin]] (Hir) is a powerful anticoagulant which is found in the leech salivary glands. It is an inhibitor of thrombin (Thr) which converts [[Fibrinogen|fibrinogen]] to [[Fibrin|fibrin]] upon blood clotting<ref>PMID:9579630</ref>. Thrombin is produced upon enzymatic cleavage of prothrombin (ProThr). '''Hirugen''' (Hirg) is a dodecapeptide of the C-terminal of Hir (sequence NDGDFEEIPEEYL). For additional details see [[Sean Swale/Human Thrombin Inhibitor]] and [[Thrombin]]. | ||
| - | + | == Relevance == | |
| + | Hirudin is an effective local treatment in patients with mild to moderate bruises<ref>PMID:11863317</ref>. Hirudin was approved as treatment of heparin-induced thrombocytopenia and unstable angina<ref>PMID:8198374</ref>. | ||
| + | |||
| + | == Structural highlights == | ||
| + | The <scene name='41/417483/Cv/4'>N-terminal tripeptide of hirudin (green) binds to the heavy chain of thrombin (magenta) and interacts with two of its active site residues: Ser195 and His57</scene><ref>PMID:1920434</ref>. | ||
== 3D Structures of Hirudin == | == 3D Structures of Hirudin == | ||
| + | [[Hirudin 3D structures]] | ||
| - | + | </StructureSection> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | == References == | |
| - | + | <references/> | |
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Current revision
| |||||||||||
References
- ↑ Fenton JW 2nd, Ofosu FA, Brezniak DV, Hassouna HI. Thrombin and antithrombotics. Semin Thromb Hemost. 1998;24(2):87-91. PMID:9579630 doi:http://dx.doi.org/10.1055/s-2007-995828
- ↑ Stamenova PK, Marchetti T, Simeonov I. Efficacy and safety of topical hirudin (Hirudex): a double-blind, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2001 Mar-Apr;5(2):37-42. PMID:11863317
- ↑ Johnson PH. Hirudin: clinical potential of a thrombin inhibitor. Annu Rev Med. 1994;45:165-77. PMID:8198374 doi:http://dx.doi.org/10.1146/annurev.med.45.1.165
- ↑ Rydel TJ, Tulinsky A, Bode W, Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol. 1991 Sep 20;221(2):583-601. PMID:1920434

